Clinical trials
Non-Muscle Invasive Bladder Neoplasms trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 14 |
| Unknown status | 11 |
| Completed | 10 |
| Not yet recruiting | 7 |
| Active, not recruiting | 5 |
| Withdrawn | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mansoura University | 5 |
| UroGen Pharma Ltd. | 4 |
| The First Affiliated Hospital with Nanjing Medical University | 3 |
| Ankara Training and Research Hospital | 2 |
| Jørgen Bjerggaard Jensen | 2 |
| AC.TA. S.r.l. | 1 |
| Al-Azhar University | 1 |
| Assiut University | 1 |
| BLAD-HYA Group | 1 |
| Bakirkoy Dr. Sadi Konuk Research and Training Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Non-Muscle Invasive Bladder Neoplasms | 50 |
| Urinary Bladder Neoplasms | 26 |
| Recurrence | 8 |
| Neoplasms | 4 |
| Urinary Bladder Diseases | 4 |
| Urologic Diseases | 3 |
| Urologic Neoplasms | 3 |
| Carcinoma | 2 |
| Disease | 2 |
| Disease Progression | 2 |
Trials
Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.